Amendment October 30, 2008

AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

Claims 1-17. (Canceled)

18. (Currently Amended) A compound having a general formula (I):

A X—Linker—O
$$R_2$$
 R_1

wherein:

 R_1 is selected from the group consisting of :

R₂ represents a hydrogen atom, an alkyl or alkenyl group containing from 3 to 6 carbon atoms;

Appl. No. 10/541,328

Atty. Ref.: 3665-149

or a -OSi(CH₃)₂tBu;

Amendment

October 30, 2008

B-represents an halogen atom, preferably chlorine, a hydroxyl group, a -O-CH₂-O-CH₃ (MOM) group, a -O-CH₂-O-CH₂-O-CH₃ (MEM) group, a -OSO₂-alkyl group

D represents an oxygen atom, NR₃, CR'R" or a sulfur atom;

X represents an oxygen atom, a sulfur atom or a radical –NR₄-;

Y represents an oxygen atom, a sulfur atom or a radical –NR₄-;

R₃ represents a hydrogen, an alkyl group, a carboxylate group, an acyl group, a carboxamide group or a SO₂-alkyl group;

R' and R", identical or different, represent a hydrogen atom or an alkyl radical;

R₄, identical or different, is selected from a group consisting of a hydrogen atom, an alkyl group having from 1 to 10 carbon atoms, an aryl and an aralkyl;

"linker" represents (CH₂)_n, wherein n represents an integer between 1 and 10 inclusive, optionally interrupted by an heteroatom (preferably N, O, S and P) or a carbonyl group, or an aryldialkyl (preferably xylenyl) group;

A represents a group selected from :

LEBLOND et al. Appl. No. 10/541,328 Atty. Ref.: 3665-149

Amendment October 30, 2008

optionally A is substituted,

its tautomers, optical and geometrical isomers, racemates, salts, hydrates and mixtures thereof.

19. (Currently Amended) The compound according to claim 18, wherein it presents one or more characteristics selected in the group consisting of :

------X is sulfur, NH- or preferably oxygen ;

———— Y is oxygen ;

- "linker" represents $(CH_2)_n$, wherein n is from 2 to 9, preferably 4 to 7, inclusive, or the meta, ortho or para-xylenyl groups, $-CH_2CH_2CH_2CH_2$ - and $-(C=O)CH_2CH_2CH_2CH_2$ -);

- R₁ is

LEBLOND et al. Appl. No. 10/541,328 Atty. Ref.: 3665-149

Amendment October 30, 2008

oxygen, sulfur, -CH₂- or NR₃, wherein R₃ [[preferably]]optionally represents H or an alkyl group (said alkyl is more specifically a methyl radical), and CH₂-B, wherein B is a -O-CH₂-O-CH₃ group or -OSO₂-alkyl group (wherein alkyl is preferably methyl) or halogen (preferably chlorine of fluorine):

- R₂ is a hydrogen atom; and
- A is a substituted group.
- 20. (Currently Amended) The compound according to claim 18, wherein A is substituted with at least one substituent, which may be selected in the group consisting of : a hydrogen atom, a halogen atom-(preferably F, Cl, or Br), a hydroxyl group, a (C₁-C₁₀)alkyl group, an alkenyl group, an (C₁-C₁₀)alkanoyl group, a (C₁-C₁₀)alkoxy group, a (C₁-C₁₀)alkoxycarbonyl group, an aryl group, an aralkyl group, an arylcarbonyl group, a mono- or poly-cyclic hydrocarbon group, a –NHCO(C₁-C₆)alkyl group, -NO₂, -CN, a NR₅R₆ group or a trifluoro(C₁-C₆)alkyl group, R₅ and R₆, independently from each other, are selected from the group consisting of a hydrogen atom, an alkyl group having from 1 to 10 carbon atoms, an aryl and an aralkyl.

Appl. No. 10/541,328

Atty. Ref.: 3665-149

Amendment

October 30, 2008

21. (Currently Amended) The compound according to claim 18, wherein A is a

substituted group and at least one of the substituents is an halogen atom, more

preferably chlorine or fluorine.

22. (Currently Amended) The compound according to claim 18, wherein at least

one of the substituents, and more preferably all the substituents, of A represents a

hydrogen atom, a methyl group, a propyl group, an ethoxy group, an halogen atom,

preferably chlorine or fluorine, or the CF₃ group.

23. (Currently Amended) The compound according to claim 18, which is

selected from the group consisting of:

2-(Tetrahydro-pyran-2-yloxymethyl)-5-[5-(7-trifluoromethyl-quinolin-4-yloxy)-

pentyloxy]-pyran-4-one (EHT 3788)

5-[5-(6-Fluoro-2-methyl-quinolin-4-yloxy)-pentyloxy]-2-(tetrahydro-pyran-2-

yloxymethyl)-4H-pyran-4-one (EHT 1593)

5-[5-(6-Fluoro-2-trifluoromethyl-quinolin-4-yloxy)-pentyloxy]-2-(tetrahydro-pyran-

2-yloxymethyl)-4*H*-pyran-4-one (EHT 1074)

5-[5-(7-Propyl-quinolin-8-yloxy)-pentyloxy]-2-(tetrahydro-pyran-2-yloxymethyl)-

4*H*-pyran-4-one (EHT 5810)

5-[5-(Benzo[b]thiophen-7-yloxy)-pentyloxy]-2-(tetrahydro-pyran-2-yloxymethyl)-

4*H*-pyran-4-one (EHT 6060)

-6-

1398287

LEBLOND et al. Appl. No. 10/541,328 Atty. Ref.: 3665-149 Amendment

October 30, 2008

2-(Tetrahydro-pyran-2-yloxymethyl)-5-[5-(7-trifluoromethyl-quinolin-4-ylsulfanyl)-pentyloxy]-4*H*-pyran-4-one (EHT 9376),

2-(Tetrahydro-pyran-2-yloxymethyl)-5-[4-(7-trifluoromethyl-quinolin-4-ylsulfanyl)-butoxy]-4*H*-pyran-4-one (EHT 4745).

2-(Tetrahydro-pyran-2-yloxymethyl)-5-[6-(7-trifluoromethyl-quinolin-4-ylsulfanyl)-hexyloxy]-4*H*-pyran-4-one (EHT 6271).

2-Hydroxymethyl-5-[5-(7-trifluoromethyl-quinolin-4-ylsulfanyl)-pentyloxy]-4*H*-pyran-4-one hydrochloride salt (EHT 1302)

2-Hydroxymethyl-5-[5-(7-trifluoromethyl-quinolin-4-ylsulfanyl)-pentyloxy]-4*H*-pyran-4-one (EHT 5909)

2-Methoxymethyl-5-[5-(7-trifluoromethyl-quinolin-4-ylsulfanyl)-pentyloxy]-4*H*-pyran-4-one (EHT 2168)

2-Chloromethyl-5-[5-(7-trifluoromethyl-quinolin-4-ylsulfanyl)-pentyloxy]-4*H*-pyran-4-one (EHT 1494)

2-(4-Methyl-piperazin-1-ylmethyl)-5-[5-(7-trifluoromethyl-quinolin-4-ylsulfanyl)-pentyloxy]-4*H*-pyran-4-one (EHT 7365),

2-Morpholin-4-ylmethyl-5-[5-(7-trifluoromethyl-quinolin-4-ylsulfanyl)-pentyloxy]-4*H*-pyran-4-one (EHT 7168)[[.]],

LEBLOND et al. Appl. No. 10/541,328 Atty. Ref.: 3665-149

Amendment October 30, 2008

5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-2-(fluoromethyl)-4*H*-pyran-4-one (EHT 8817)

5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-2-((piperidin-1-yl)methyl)-4*H*-pyran-4-one (EHT 9317)

5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-2-(thiomorpholino-methyl)-4*H*-pyran-4-one (EHT 5430)

2-((Diethylamino)methyl)-5-(5-(7-(trifluoromethyl)quinolin-4-ylthio)pentyloxy)-4*H*-pyran-4-one (EHT 7370)

5-(5-(Quinazolin-4-yloxy)pentyloxy)-2-(morpholinomethyl)-4*H*-pyran-4-one (EHT 3726)

5-(5-(Quinazolin-4-yloxy)pentyloxy)-2-((4-methylpiperazin-1-yl)methyl)-4*H*-pyran-4-one (EHT 4063)

4-[5-(6-Morpholin-4-ylmethyl-4-oxo-4*H*-pyran-3-yloxy)-pentyloxy]-7-trifluoromethyl-quinoline-3-carboxylic acid ethyl ester (EHT 8935)

5-(5-(Quinazolin-4-yloxy)pentyloxy)-2-((pyrrolidin-1-yl)methyl)-4*H*-pyran-4-one (EHT 5317)

5-(5-(8-(Trifluoromethyl)quinolin-4-yloxy)pentyloxy)-2-((4-methylpiperazin-1-yl)methyl)-4*H*-pyran-4-one (EHT 5847)

LEBLOND et al. Appl. No. 10/541,328 Atty. Ref.: 3665-149 Amendment

October 30, 2008

5-(5-(8-(Trifluoromethyl)quinolin-4-yloxy)pentyloxy)-2-(morpholinomethyl)-4*H*-pyran-4-one (EHT 4687)

5-(5-(7-(Trifluoromethyl)quinolin-4-yloxy)pentyloxy)-2-(morpholinomethyl)-4*H*-pyran-4-one (EHT 3411)

5-(5-(7-(Trifluoromethyl)quinolin-4-yloxy)pentyloxy)-2-((4-methylpiperazin-1-yl)methyl)-4*H*-pyran-4-one (EHT 0079)

5-(5-(6-(Trifluoromethyl)quinolin-4-yloxy)pentyloxy)-2-(morpholinomethyl)-4*H*-pyran-4-one (EHT 1426)

4-[5-(6-(4-Methyl-piperazin-1-ylmethyl)-4-oxo-4*H*-pyran-3-yloxy)-pentyloxy]-7-trifluoromethyl-quinoline-3-carboxylic acid ethyl ester (EHT 8791)

4-[5-(6-(4-Methyl-piperazin-1-ylmethyl)-4-oxo-4*H*-pyran-3-yloxy)-pentyloxy]-7-trifluoromethyl-quinoline-3-carboxylic acid ethyl ester

5-((3-((7-(Trifluoromethyl)quinolin-4-ylthio)methyl)phenyl)methoxy)-2-(morpholinomethyl)-4*H*-pyran-4-one (EHT 2725).

5-((4-((7-(Trifluoromethyl)quinolin-4-ylthio)methyl)phenyl)methoxy)-2-(morpholinomethyl)-4*H*-pyran-4-one (EHT 2218),

5-((2-((7-(Trifluoromethyl)quinolin-4-ylthio)methyl)phenyl)methoxy)-2-(morpholinomethyl)-4*H*-pyran-4-one (EHT 9069),

LEBLOND et al. Appl. No. 10/541,328 Atty. Ref.: 3665-149 Amendment October 30, 2008

5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-2-((4-acetylpiperazin-1-yl)methyl)-4H-pyran-4-one (EHT 3980).

4-((5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-4-oxo-4*H*-pyran-2-yl)methyl)-*N*,*N*-diethylpiperazine-1-carboxamide (EHT 5743),

5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-2-((4-(pivaloyl)piperazin-1-yl)methyl)-4*H*-pyran-4-one (EHT 0785),

4-((5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-4-oxo-4*H*-pyran-2-yl)methyl)-*N*,*N*-di-isopropylpiperazine-1-carboxamide (EHT 0566),

5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-2-((4-methylsulfonylpiperazin-1-yl)methyl)-4*H*-pyran-4-one (EHT 8366),

4-((5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-4-oxo-4*H*-pyran-2-yl)methyl)-*N-tert*-butylpiperazine-1-carboxamide (EHT 3664),

4-((5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-4-oxo-4*H*-pyran-2-yl)methyl)-*N*-methylpiperazine-1-carboxamide (EHT 4495).

5-(6-(Morpholinomethyl)-4-oxo-4*H*-pyran-3-yloxy)-*N*-(7-(trifluoromethyl)quinolin-4-yl)pentanamide (EHT 6037)

5-(2-(7-(Trifluoromethyl)quinolin-4-ylthio)ethoxy)ethoxy)-2-(morpholinomethyl)-4*H*-pyran-4-one (EHT 0371),

LEBLOND et al. Appl. No. 10/541,328 Atty. Ref.: 3665-149 Amendment

October 30, 2008

5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-2-(morpholinomethyl)-4*H*-pyran-4-one dihydrochloride (EHT 1864),

5-((3-((7-(Trifluoromethyl)quinolin-4-ylthio)methyl)phenyl)methoxy)-2-(morpholinomethyl)-4*H*-pyran-4-one dihydrochloride (EHT 0434),

tert-Butyl 4-((5-(5-(7-(trifluoromethyl)quinolin-4-ylthio)pentyloxy)-4-oxo-4*H*-pyran-2-yl)methyl)piperazine-1-carboxylate (EHT 9358),

tert-Butyl 4-((5-(5-(7-chloroquinolin-4-yloxy)pentyloxy)-4-oxo-4H-pyran-2-yl)methyl)piperazine-1-carboxylate (EHT 2580)

5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-2-((4-methylpiperazin-1-yl)methyl)-4*H*-pyran-4-one trihydrochloride (EHT 9241).

5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-2-((piperazin-1-yl)methyl)-4*H*-pyran-4-one trihydrochloride (EHT 8560),

5-(5-(7-Chloroquinolin-4-yloxy)pentyloxy)-2-((piperazin-1-yl)methyl)-4H-pyran-4-one (EHT 0872)

5-(2-(7-(Trifluoromethyl)quinolin-4-ylthio)ethoxy)-2-((tetrahydro-2*H*-pyran-2-yloxy)methyl)-4*H*-pyran-4-one (EHT 5575),

5-(8-(7-(Trifluoromethyl)quinolin-4-ylthio)octyloxy)-2-((tetrahydro-2*H*-pyran-2-yloxy)methyl)-4*H*-pyran-4-one (EHT 1006), and

Appl. No. 10/541,328

Atty. Ref.: 3665-149

Amendment

October 30, 2008

5-(7-(7-(Trifluoromethyl)quinolin-4-ylthio)heptyloxy)-2-((tetrahydro-2*H*-pyran-2-

yloxy)methyl)-4*H*-pyran-4-one (EHT 8883)

5-(2-(7-(Trifluoromethyl)quinolin-4-yloxy)ethoxy)-2-(morpholinomethyl)-4H-pyran-

4-one (EHT 6892).

24. (Previously Presented) The compound according to claim 23, which is EHT

9241, its free base EHT 7365, EHT 8560, EHT 1864, its free base EHT 7168 or EHT

5743.

25. (Previously Presented) A pharmaceutical composition comprising at least

one compound according to claim 18 and a pharmaceutically acceptable vehicle or

support.

26. (Withdrawn) The composition according to claim 25, for the treatment of a

disease associated with abnormal cell proliferation or of a disease associated with

unregulated angiogenesis.

27. (Withdrawn) A composition according to claim 25, for the treatment of

cancers, restenosis, arthritis, diabetes, ocular-diseases or especially retinopathies.

28. (Withdrawn) A composition according to claim 25, for the treatment of solid

tumors or lymphoid tumors.

29. (Withdrawn) The composition according to claim 25, wherein for the

treatment of cancers selected from prostate cancer, ovarian cancer, pancreas cancer,

- 12 -

1398287

Appl. No. 10/541,328

Atty. Ref.: 3665-149

Amendment

October 30, 2008

lung cancer, breast cancer, liver cancer, head and neck cancer, colon cancer, bladder

cancer, non-Hodgkin 's lymphoma cancer, leukemia and melanoma.

30. (Withdrawn) The composition according to claim 25, for reducing cancer cell

proliferation.

31. (Withdrawn) The composition according to claim 25, for treating metastatic

cancers in a subject.

32. (Withdrawn) The composition according to claim 25, for treating diabetic

retinopathies, retinal degenerative diseases, or Age-Related Macular Degeneration

(ARMD).

33. (Withdrawn) The composition according to claim 25, for treating arthritis.

34. (Withdrawn) The composition according to claim 25, for treating leukemia, in

particular acute lymphoblastic leukemia, chronic myeloid leukemia, acute myeloid

leukemia.

35. (Withdrawn) A method for the treatment of a disease associated with

abnormal cell proliferation or of a disease associated with unregulated angiogenesis, by

administering to a subject in need of such treatment an effective amount of at least one

compound of formula (I) as defined in claim 18.

36. (new) The compound of claim 18 wherein said heteroatom is selected from

the group consisting of N, O, S and P, or said aryldialkyl is xylenyl.

37. (new) The compound of claim 19 wherein n is a value of 4 to 7.

- 13 -

1398287

Appl. No. 10/541,328 Atty. Ref.: 3665-149

Amendment

October 30, 2008

- 38. (new) The compound of claim 19 wherein said alkyl is a methyl radical.
- 39. (new) The compound of claim 20 wherein said halogen is F, Cl or Br.
- 40. (new) The compound of claim 21 wherein said halogen atom is chlorine or fluorine.
- 41. (new) The compound of claim 22 wherein all of the substituents of A represents a hydrogen atom, a methyl group, a propyl group, an ethoxy group, an halogen atom or the CF₃ group.
- 42. (new) The compound of claim 22 wherein said halogen atom is chlorine or fluorine.